BioPharma Resources

Drug Trial Radar · NCT07298447

Donidalorsen Treatment in Children With Hereditary Angioedema

An Open-Label Study of Donidalorsen in Pediatric Patients Age 2 to Less Than 12 Years Old With Hereditary Angioedema

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Apr 21, 2026

Primary completion

Jun 2029

Study completion Jun 2029

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Dec 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of donidalorsen in pediatric participants with hereditary angioedema (HAE) Type I (HAE-1) or Type II (HAE-2).

Conditions

  • Hereditary Angioedema (HAE)

Interventions

  • DonidalorsenDrug

    Donidalorsen will be administered by subcutaneous (SC) injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs)Time frame: over the period of approximately 17 months
  2. Maximum Plasma Concentration (Cmax) of DonidalorsenTime frame: over the period of approximately 17 months
  3. Maximum Time to Reach Cmax (Tmax) of DonidalorsenTime frame: over the period of approximately 17 months
  4. Trough Plasma Concentration (Ctrough) of DonidalorsenTime frame: over the period of approximately 17 months

Locations

18 sites in 5 countries. Site status is shown where the registry gives one.

  • Ionis Investigative Site

    Santa Monica, California · Recruiting

  • Ionis Investigative Site

    Miami, Florida · Recruiting

  • Ionis Investigative Site

    Baton Rouge, Louisiana · Recruiting

  • Ionis Investigative Site

    St Louis, Missouri · Recruiting

  • Ionis Investigative Site

    Cincinnati, Ohio · Recruiting

  • Ionis Investigative Site

    Cleveland, Ohio · Recruiting

  • Ionis Investigative Site

    Hershey, Pennsylvania · Recruiting

  • Ionis Investigative Site

    West Allis, Wisconsin · Recruiting

  • Ionis Investigative Site

    Murdoch, Australia · Recruiting

  • Ionis Investigative Site

    South Brisbane, Queensland, Australia · Recruiting

  • Ionis Investigative Site

    Clayton, Victoria, Australia · Recruiting

  • Ionis Investigative Site

    Milan, Italy · Recruiting

  • Ionis Investigative Site

    Padova, Italy · Recruiting

  • Ionis Investigative Site

    Roma, Italy · Recruiting

  • Ionis Investigative Site

    San Donato Milanese, Italy · Recruiting

  • Ionis Investigative Site

    Krakow, Poland · Recruiting

  • Ionis Investigative Site

    Warsaw, Poland · Recruiting

  • Ionis Investigative Site

    Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.